Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,523 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,523 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $139,171.74. Following the completion of the sale, the chief financial officer now owns 73,039 shares in the company, valued at approximately $6,674,303.82. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total value of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The shares were sold at an average price of $67.73, for a total value of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The stock was sold at an average price of $65.09, for a total value of $210,566.15.

Natera Stock Performance

Shares of Natera stock opened at $91.04 on Wednesday. The company has a market cap of $10.99 billion, a PE ratio of -24.02 and a beta of 1.37. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The business has a 50 day moving average price of $86.40 and a 200-day moving average price of $66.49. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $98.82.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. The company had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Equities analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Several institutional investors have recently modified their holdings of NTRA. National Bank of Canada FI bought a new position in shares of Natera in the third quarter valued at approximately $1,932,000. CWM LLC grew its holdings in shares of Natera by 224.4% in the third quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 911 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Natera by 1,503.2% in the third quarter. SG Americas Securities LLC now owns 97,973 shares of the medical research company’s stock valued at $4,335,000 after acquiring an additional 91,862 shares in the last quarter. Ellsworth Advisors LLC bought a new position in Natera during the third quarter valued at $364,000. Finally, Xponance Inc. grew its holdings in Natera by 1.8% during the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock valued at $642,000 after purchasing an additional 261 shares during the period. 99.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research note on Friday, April 5th. The Goldman Sachs Group upped their price target on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Tuesday. Raymond James downgraded Natera from a “strong-buy” rating to an “outperform” rating and upped their price target for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. Finally, Piper Sandler upped their price target on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.